Comparison of PSMA-ligand PET/CT and multiparametric MRI for the detection of recurrent prostate cancer in the pelvis.

Afshar-Oromieh, Ali; Vollnberg, Bernd; Alberts, Ian; Bähler, Alexandrine; Sachpekidis, Christos; Dijkstra, Lotte; Haupt, Fabian; Boxler, Silvan; Gross, Tobias; Holland-Letz, Tim; Thalmann, George; Heverhagen, Johannes; Rominger, Axel; Härmä, Kirsi; Maurer, Martin H. (2019). Comparison of PSMA-ligand PET/CT and multiparametric MRI for the detection of recurrent prostate cancer in the pelvis. European journal of nuclear medicine and molecular imaging, 46(11), pp. 2289-2297. Springer-Verlag 10.1007/s00259-019-04438-w

[img] Text
Comparison_PSMA.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (6MB) | Request a copy

PURPOSE So far, there have been very few studies which provide a direct comparison between MRI and PSMA-ligand PET/CT for the detection of recurrent prostate cancer (rPC). This present study therefore aims to provide further clinical data in order to resolve this urgent clinical question, and thereby strengthen clinical recommendations. METHODS A retrospective analysis was performed for patients who were scanned at our institution with whole-body PSMA-PET/CT (tracer: 68Ga-PSMA-11) between January 2017 and September 2018 in order to detect rPC. Amongst them, 43 underwent an additional pelvic MRI within 2 months. Both modalities were compared as follows: a consensus read of the PET data was performed by two nuclear physicians. All lesions were recorded with respect to their type and localization. The same process was conducted by two radiologists for pelvic MRI. Thereafter, both modalities were directly compared for every patient and lesion. RESULTS Overall, 30/43 patients (69.8%) presented with a pathologic MRI and 38/43 (88.4%) with a pathologic PSMA-PET/CT of the pelvis. MRI detected 53 pelvic rPC lesions (13 of them classified as "uncertain") and PSMA-PET/CT detected 75 pelvic lesions (three classified as "uncertain"). The superiority of PSMA-PET/CT was statistically significant only if uncertain lesions were classified as false-positive. CONCLUSIONS PSMA-PET/CT detected more pelvic lesions characteristic for rPC when compared to MRI. In order to detect rPC, a potential future scenario could be conducting first a PSMA-PET/CT. Combining the advantages of both modalities in hybrid PET/MRI scanners would be an ideal future scenario.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Clinic of Nuclear Medicine
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Urology
04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Institute of Diagnostic, Interventional and Paediatric Radiology

UniBE Contributor:

Afshar Oromieh, Ali; Vollnberg, Bernd Olaf; Alberts, Ian Leigh; Bähler, Alexandrine; Sachpekidis, Christos; Haupt, Fabian; Boxler, Silvan; Gross, Tobias; Thalmann, George; Heverhagen, Johannes; Rominger, Axel Oliver; Härmä, Kirsi Hannele and Maurer, Martin

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1619-7070

Publisher:

Springer-Verlag

Language:

English

Submitter:

Maria de Fatima Henriques Bernardo

Date Deposited:

09 Aug 2019 11:13

Last Modified:

03 Sep 2019 01:32

Publisher DOI:

10.1007/s00259-019-04438-w

PubMed ID:

31350604

Uncontrolled Keywords:

68Ga-PSMA-11 MRI PET/CT PSMA Prostate cancer Prostate-Specific Membrane Antigen

BORIS DOI:

10.7892/boris.132313

URI:

https://boris.unibe.ch/id/eprint/132313

Actions (login required)

Edit item Edit item
Provide Feedback